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Reconsidering Outcomes After Transcatheter Aortic Valve Implantation
Following The Valve Academic Research Consortium Definitions
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Schirmer1, Stefan Blankenberg2, Hermann Reichenspurner1, Hendrik Treede1
1University Heart Center Hamburg - Department of Cardiovascular Surgery,
Hamburg, Germany; 2University Heart Center Hamburg - Department of General
and Interventional Cardiology, Hamburg, Germany
Background: Reporting of outcomes after transcatheter aortic valve implantation
(TAVI) has been variable. To allow comparison of these multiple non-randomized trials,
the Valve Academic Research Consortium (VARC) recently introduced standardized
endpoint definitions. We sought to re-evaluate our single-center experience with TAVI
following the VARC definitions.
Methods: From 03/2008 to 06/2011, 285 patients underwent TAVI with Edwards
Sapien (ES; Edwards Lifesciences, Irvine, CA) or CoreValve (CV; Medtronic,
Minneapolis, MN) devices at our institution. Data were gathered prospectively at
baseline, discharge, 30 days and 1 year after TAVI. Retrospective analysis was done
according to endpoints recently defined by the VARC.
Results: TAVI was performed via the transapical (TA) approach using the ES in 164
(57.5%) and transfemoral (TF) access in 121 (42.5%; ES: 65.3%, CV: 34.7%) patients.
Mean age was 79.9±9.1 years and the TA group showed a higher risk profile with a
log EuroSCORE of 25.6±12.8% (TA) vs. 20.4±12.4% (TF; p=0.002). All-cause
mortality was 11.1% (TF) vs. 11.2% (TA) at 30 days and 28.1% (TF) vs. 29.1% (TA)
at 1 year. Device success was achieved in 86.8% (TF) and 85.4% (TA) of TAVI
procedures and 30-day mortality was 8.1% and 10.1% in these patients. The combined
30-day safety endpoint was reached in 15.7% of TF and 20.1% of TA cases.
Periprocedural myocardial infarction occurred in 0.8% (TF) and 0.6% (TA), major
stroke in 5.0% (TF) and 5.5% (TA), and severe acute kidney injury in 3.3% (TF) and
4.3% (TA). Access site complications were observed in 10.7% (TF) and 3.7% (TA).
Conduction disorders required permanent pacemaker implantation in 14.9% (TF; ES:
7.6%, CV: 28.6%) and 13.4% (TA) of patients. NYHA class improved by 1.1±0.7 (TF)
and 0.9±0.6 (TA) at 30-day and 0.9±0.6 (TF) and 1.1±0.9 (TA) at 1-year follow-up.
Conclusion: According to standardized endpoint definitions published by the VARC,
TAVI with TA and TF approaches can be performed with comparable survival.
Nevertheless, the higher risk profile in TA patients seems to find its expression in a
higher combined 30-day safety endpoint although this was not reflected in delayed
clinical improvement. Device success was not a predictor of survival in this patient
series.
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Background: Older age is a predictor of early and late mortality following surgical
aortic replacement. Patients undergoing transcatheter aortic valve implantation (TAVI)
are elderly and associated with multiple comorbidities. We aim to investigate whether
differences exist in clinical presentation and outcomes according to age in patients
undergoing TAVI.
Methods: From June 2007 to June 2010 consecutive TAVI patients were prospectively
entered into a dedicated database. Patients were subdivided into age tertiles (A1 to A3)
and these subgroups were subsequently examined for any differences in baseline
characteristics, and 30-day and 6-month mortality. Kaplan Meier curves were used to
estimate survival in all groups.
Results: A total of 501 patients underwent TAVI (n=342 CoreValve and n=159
Edwards SAPIEN). The age tertiles were identified as < 78 years (A1, n=164 patients),
79 to 83 years (A2, n=173 patients) and older than 84 years (A3, n=164 patients). As
compared to A1 patients, A3 patients had higher logistic EuroSCORES (23.4±12.7 vs.
15.7±11.0%, p<0.001), higher STS scores (7.6±4.2 vs. 4.2±3.4%, p<0.001), higher
baseline creatinine levels (1.3±0.5 vs. 1.2±0.73 mg/dl, p=0.03) and more coronary
artery disease (64 vs. 47.6%, p=0.008). The 30-day mortality was 4-fold higher in A3
than in A1 (11.4 vs. 3.6%, p=0.03) whereas there was no significant difference in
mortality observed between A3 and A1 at 6-month follow-up (19 to 15%, p=0.45).
Conclusion: In this TAVI cohort, the 30-day mortality was 4-fold higher in those
patients older than 84 years than in those less than 78 years; these differences were no
longer appreciated at 6-month follow-up.
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Balloon Aortic Valvuloplasty as a Bridging Thearpy to Aortic Valve
Replacement or Transcatheter Aortic Valve Implantation
Michael Tempelhof, Nirat Beohar, Chris S Malaisrie, Patrick M McCarthy, Charles
J Davidson
Cardiology, Northwestern University, Chicago, IL
Background: Balloon aortic valvuloplasty (BAV) is a therapeutic option for patients
with severe aortic stenosis (AS). Clinical outcomes with BAV are limited by restenosis
and high mortality rates as compared to surgical aortic valve replacement (AVR). AVR
is the recommended therapy for patients with severe AS. BAV as a bridge to AVR for
high-surgical risk AS patients has been reported. Transcatheter aortic valve
implantation (TAVI) has equal safety and efficacy outcomes compared to AVR.
Currently, there is a paucity of information describing the utilization of BAV as a bridge
to definitive therapy in the modern era of AVR and TAVI.
Methods: We compared the safety and clinical outcomes associated with BAV alone,
to BAV as a bridge to AVR or to TAVI among a high-surgical risk cohort of patients
with severe AS.
Results: The medical records of patients who received a BAV procedure for severe
AS were analyzed and included in the study (80 patients). Baseline STS scores were
higher in the TAVI cohort; other baseline demographics were similar across study
cohorts (Table 1). Ten patients were bridged to AVR and fifteen patients were
successfully bridged to TAVI. Clinical outcomes of all cause death, cardiovascular
death, death 30 days after BAV and rehospitalization for heart failure were compared
among the 3 study cohorts (Table 1). There was a significant higher rate of all cause
death, cardiovascular death and rehospitalization for heart failure among the BAV-
alone cohort compared to the BAV-bridge cohorts (Table 1). Complications rates were
low and occurred only in the BAV-alone cohort (Table 1).
Conclusion: BAV is an effective and safe therapeutic option as a bridge to AVR or
TAVI. BAV should be considered prior to AVR or TAVI in high-surgical risk patients
with severe AS.
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Optimal projection for Transcatheter Aortic Valve Implantation determined
from the reference projection angles
James Andrew Cockburn, Uday Trivedi, Adam De Belder, David Hildick-Smith
Cardiology Research Unit, Sussex Cardiac Centre, Brighton, United Kingdom
Background: An optimal fluoroscopic working view projection (OP) with all three
aortic sinuses aligned is crucial during trans-catheter aortic valve implantation (TAVI).
The aim of this study was to identify simple reference projection angles, which would
act as a starting point for the operator to help determine OP in patients.
Methods: Procedural outcome data was collected prospectively from 50 patients
undergoing TAVI. Optimal angiographic deployment angles were achieved for all
patients by starting in an anteroposterior caudal 15 degrees projection and then
adjusting according to the initial image, with multiple small volume contrast injections
undertaken to determine when all 3 aortic cusps were aligned (OP).
Results: OP angles for the 50 cases were plotted.(Figure 1)Regression analysis enabled
a regression line to be calculated. The equation for the regression line was defined as
caudal intercept -14.8±1.9 (SEcoefficient), p<0.0001, slope of regression line +
0.453±0.1 (SEcoefficient), p<0.002).
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Figure 1: OP projections
Conclusion: As the regression line and its equation represents an acceptable estimate
of the true relationship between Cranial/Caudal and LAO/RAO, to determine OP while
remaining around the regression line we suggest starting in LAO = 8.9, Caudal = -10.6
(the mean of these two variables) and increasing the caudal angle by approximately
0.5 degrees for every increase of 1 degree of the LAO or decreasing the caudal angle
by 0.5 degree for every decrease of 1 degree in LAO until all 3 aortic sinuses are in
line which represents OP.
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Efficacy and safety of Transcatheter Aortic Valve Replacement: Northern
Ireland Experience
Ganesh Manoharan, Mark S Spence, Vivek Kodoth, Christine Maguire, Lynn
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Background: Transcatheter aortic valve replacement (TAVR) is increasingly being
advocated for treating surgically inoperable or high risk patients with severe
symptomatic aortic stenosis. Its use in treating failing surgical aortic bioprosthetic valve
is also increasing. We report our TAVR findings in Northern Ireland.
Methods: All patients who met the clinically and technical criteria (annulus ranging
from 19.5 to 27mm; vascular access more than 6mm in diameter) were discussed and
approved for the procedure at a joint multidisciplinary meeting. Unless a patient
required a cut-down for vascular access, all cases were performed under local
anaesthesia and without sedation. All patients were managed immediately post-
procedure in the Coronary Care Unit. All patients underwent clinical,
echocardiographic assessments and 6 minute walk test at pre-procedure, pre-discharge,
30day, 3month, 6 month, 12 month and 6 monthly thereafter.
Results: A total of 120 patients (average age: 83yrs old; Average logistic euroscore:24)
were planned for TAVR. Procedural success was 98% (1 procedural related mortality
and the valve was not delivered in 1 patient due to access difficulty), with 91.8%
performed under local anaesthesia. Percutaneous vs access cutdown (subclavian or
femoral artery) were 91.8% and 8.2% respectively. TAVI was performed for failing
native aortic valve in 94.1% and bioprosthetic valve (valve-in-valve) in 5.9% of
patients. The 30-day, 6-month and 1-year all cause mortality were 4.7%, 7% and 11.6%
respectively. Minor vascular access complication (by VARC definition) was 2.4%
(major=0%). Clinical stroke was observed in X2 patients and gut ischaemia presumed
embolic event was observed in 1 patient: all were in atrial fibrillation and were either
unable to be prescribed warfarin or had it stopped for another procedure.
Conclusion: Conclusions: In carefully pre-selected patients, TAVR performed by a
dedicated team is safe and efficacious. Performing the procedure under local
anaesthesia has merits. Pre-existence of untreated atrial fibrillation correlates with
increased risk of embolic events.
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The STS-Score outperforms the EuroSCORE in predicting short-term outcome
following transcatheter valve implantation, but does not predict long-term
outcome
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Background: Transcatheter aortic valve implantation (TAVI) was developed as new
therapy for inoperable patients and surgical high-risk patients. After successful index
procedure further prognosis might be influenced mainly by comorbidities. Therefore,
patient selection seems to be crucial in order to improve short and long-term outcome.
The aim of this study was to identify predictors of adverse outcome
Methods: Until today a total of 132 transfemoral (TF) and 122 transapical TAVI
procedures were performed at the University Hospital Frankfurt. Beyond evaluation
of clinical and functional characteristics Euroscore, STS and Braden-Score were
calculated for each of these patients.
Results: Observed 30-day Mortality was 5% in the femoral and 15% in the apical
patients. In the transfemoral cohort the EuroSCORE was significantly lower compared
to the transapical cohort (16.5±12.6 vs. 22.7±15.8 ; p=0.001). Patients with a STS-
Score (range 34.9) above the median (5.4) experienced a nearly threefold elevated
30-day-mortality (HR 2.78; p=0.048), whereas the logistic EuroSCORE (HR 1.74;
p=0.237) and the Braden-Score (HR 0.79; p=0.629) were no predictors. Furthermore
age above 80 years is associated with a dramatically elevated 30-day-mortality (HR
6.35; p=0.013). The hazard ratio (HR) of TF cases was 0.38 (p=0.044) compared to
TA cases. In a multivariable analysis only age above 80 years remains as independent
predictor of adverse acute outcome (HR 5.27; p=0.027). In a subgroup of 162 patients
predictors of long-term mortality were calculated (follow-up 379±341 days). These
analysis was restricted patients discharged alive (follow-up 379±341 days). Neither
the STS-Score (HR 1.08; p=0.837) nor the EuroSCORE (HR 1.36; p=0.470) or age
(HR 0.74; p=0.435) were predictors of long-term mortality. No any other independent
risk predicting factors including analysis of echocardiographic data could be found.
Conclusion: The STS-Score outperforms the logistic EuroSCORE in predicting 30-
day-mortality following TAVI, but does not predict long-term outcome.
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Outcome comparison of non-transfemoral approaches for transcatheter aortic
valve implantation utilizing CoreValve
Pak Hei Chan1, Carlo Di Mario1, Simon W Davies1, Andrea Kelleher2, Richard
Trimlett3, Neil Moat3
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Background: Transcatheter aortic valve implantation (TAVI) via transfemoral route
had been demonstrated with most favourable clinical outcomes. However, for patients
with no suitable transfemoral access, other approaches would be adopted, namely
Trans-axillary (TAx), Direct aortic (DA) utilizing CoreValve and Transapical (TA)
utilizing Edwards-SAPIEN valve. We report our experience and patient outcome in
TAVI via non-transfemoral approach utilizing CoreValve.
Methods: For patients accepted for TAVI, access route suitability would be assessed
by conventional and CT angiograms, taking into account the vessel size, tortuosity,
presence of peripheral vascular disease (PVD) and patent LIMA graft. TAVI was
performed under general anaesthesia and in usual fashion as described in literature.
Procedural success was defined as successful implantation of CoreValve without >2+
aortic regurgitation (AR). Patients were followed up clinically and with
echocardiography at 30 days and 1 year.
Results: Out of 197 patients undergone TAVI in our institution, 33 patients (22 males,
66.7%) had TAVI via non-transfemoral approach: 10 direct aortic (5.1%) and 23 trans-
axillary (11.7%). The two groups were not different in terms of age (p=0.7), left
ventricular ejection fraction (LVEF) (p=0.06) and prevalence of PVD (p=0.9). Logistic
EuroSCORE was 26.3±12.3 for DA and 12.4±8.1 for TAx approaches (p=0.13). 100%
procedural success was achieved in both groups. There was no difference in terms of
incidence of paravalvular AR post-TAVI (p=0.49). 30-day mortality was 10% in DA
group (1 patient died from post-operative ischaemic stroke at 23 days) and 4.3% in
TAx group (1 patient with severe PVD died from ischaemic bowel due to thrombosis
of superior mesenteric artery at 29 days). 1-year mortality was 20% in DA group and
13% in TAx group (p=0.34).
Conclusion: Among different non-transfemoral approaches for TAVI utilizing
CoreValve, both direct aortic and trans-axillary approaches were shown to be safe and
feasible alternatives to transfermoral approach in patients with no suitable femoral
access.
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